An Oral GnRH Antagonist for Endometriosis — A New Drug for an Old Disease
letter
OA: closed
CC0
⤵ 10 in-corpus citations
AI-generated summary
This study investigated the efficacy of an oral GnRH antagonist for treating endometriosis, a condition driven by estrogen and causing chronic pelvic pain and infertility in women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis, a chronic gynecologic disease characterized by attachment and proliferation of endometrial cells outside the endometrial cavity, occurs in 6 to 10% of women of reproductive age1 and is associated with dysmenorrhea, nonmenstrual pelvic pain, dyspareunia, and infertility. The disease is also associated with an increased prevalence of depression, reduction in sexual satisfaction, disrupted personal relations, and loss of work leading to substantial economic cost. The pathogenesis is incompletely understood, but estrogen is integral to endometrial proliferation and function. Although surgical treatment of endometriosis-associated pelvic pain results in symptomatic improvement in most patients,2 medical treatment remains the mainstay of long-term . . .
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (6)
- Aromatase inhibitors for the treatment of endometriosis via openalex
- Laparoscopic excision of endometriosis: A randomized, placebo-controlled trial via openalex
- Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- W2148368274 via openalex
- W4211081176 via openalex
Cited by (10)
- The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications 2024
- A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment 2023
- Novel pharmacological therapies for the treatment of endometriosis 2022
- Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysis 2021
- Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase <scp>III</scp> Trials to an Older Real‐World Population 2020
- Medikamentöse Behandlung der Endometriose 2020
- Current and emerging treatment options for endometriosis 2018
- Elagolix for endometriosis: all that glitters is not gold 2018
- Endometriosis 2018
- Current and Emerging Therapeutics for the Management of Endometriosis 2018
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:20:19.560968+00:00
License: CC0
· commercial use OK